weekly_roundup

BioTechSign Daily Catalyst Roundup - November 08, 2026

Top BioTechSign catalyst names today: ITCI, BGNE, DCPH, SRPT, EYPT, RNA. FDA, clinical trial, grade-change, dilution, and sentiment signals.

BiotechSign AnalysisNovember 8, 2026

Daily Biotech Catalyst Digest: November 08, 2026

ITCI leads the current BioTechSign screen at 100.0/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.

Top Catalyst Scores

TickerCompanyScoreGradeStrongest Inputs
ITCIIntra-Cellular Therapies100.0Aclinical activity 100%
BGNEBeiGene Ltd100.0Apublication signal 100%, clinical activity 100%
DCPHDeciphera Pharmaceuticals100.0Aclinical activity 100%
SRPTSarepta Therapeutics85.9Aclinical activity 100%, short interest 70%, dilution risk 48%
EYPTEyePoint, Inc.84.8Aclinical activity 100%, short interest 70%, dilution risk 43%
RNAAvidity Biosciences84.6Apublication signal 100%, clinical activity 100%, short interest 70%

Recent Grade-Change Queue

  • SLDB (Solid Biosciences) currently grades F with a 34.8/100 catalyst score. Main inputs: publication signal 100%, short interest 70%, dilution risk 61%.
  • PRQR (ProQR Therapeutics) currently grades F with a 23.7/100 catalyst score. Main inputs: publication signal 100%, dilution risk 46%, clinical activity 17%.
  • PASG (Passage Bio) currently grades D with a 43.8/100 catalyst score. Main inputs: publication signal 100%, dilution risk 53%, short interest 10%.
  • LYEL (Lyell Immunopharma) currently grades F with a 30.8/100 catalyst score. Main inputs: publication signal 100%, dilution risk 69%, short interest 50%.
  • MBRX (Moleculin Biotech) currently grades F with a 21.7/100 catalyst score. Main inputs: dilution risk 92%, publication signal 80%, clinical activity 12%.
  • IMV (IMV Inc) currently grades F with a 25.0/100 catalyst score. Main inputs: clinical activity 25%.
  • GERN (Geron Corporation) currently grades D with a 45.0/100 catalyst score. Main inputs: publication signal 100%, dilution risk 50%, short interest 50%.
  • GLUE (Monte Rosa Therapeutics) currently grades F with a 34.9/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, dilution risk 54%.

What To Watch

Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.